Rational Design of an Epstein-Barr Virus Vaccine Targeting the Receptor-Binding Site

Cell

Volumn 162, Issue 5, 2015, Pages 1090-1100

  Kanekiyo, Masaru ^a   Bu, Wei ^a   Joyce, M Gordon ^a   Meng, Geng ^b   Whittle, James R R ^a,d   Baxa, Ulrich ^c   Yamamoto, Takuya ^a,e   Narpala, Sandeep ^a   Todd, John Paul ^a   Rao, Srinivas S ^a,f   McDermott, Adrian B ^a   Koup, Richard A ^a   Rossmann, Michael G ^b   Mascola, John R ^a   Graham, Barney S ^a   Cohen, Jeffrey I ^a   Nabel, Gary J ^a,f  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^b PURDUE UNIVERSITY   (United States)

^c FREDERICK NATIONAL LABORATORY FOR CANCER RESEARCH   (United States)

^d GEORGE WASHINGTON UNIVERSITY   (United States)

^e Health and Nutrition   (Japan)

^f SANOFI   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENT RECEPTOR; COMPLEMENT RECEPTOR 2; EPSTEIN BARR VIRUS VACCINE; GLYCOPROTEIN 350 220 D 123 ENCAPSULIN; GLYCOPROTEIN 350 220 D 123 FERRITIN; GLYCOPROTEIN 350 220 ECTODOMAIN VACCINE; GLYCOPROTEIN 350 ANTIBODY; NANOPARTICLE; NEUTRALIZING ANTIBODY; PROTEIN ANTIBODY; RECOMBINANT PROTEIN; UNCLASSIFIED DRUG; VIRUS ANTIBODY; VIRUS LIKE PARTICLE VACCINE; COMPLEMENT COMPONENT C3D RECEPTOR; HERPES VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY COMBINING SITE; ANTIBODY RESPONSE; ANTIBODY TITER; ANTIGEN EXPRESSION; ANTIGEN RECOGNITION; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG ANTIGENICITY; DRUG BINDING SITE; DRUG DESIGN; DRUG EFFICACY; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG TARGETING; EPSTEIN BARR VIRUS INFECTION; FEMALE; IMMUNOGENICITY; INFECTION PREVENTION; MOUSE; NONHUMAN; PRIMATE MODEL; PRIORITY JOURNAL; TREATMENT RESPONSE; VACCINATION; VIRUS ENTRY; VIRUS NEUTRALIZATION; ANIMAL; BAGG ALBINO MOUSE; CHEMISTRY; EPSTEIN BARR VIRUS; GENETICS; IMMUNOLOGY; ISOLATION AND PURIFICATION; MACACA FASCICULARIS; ULTRASTRUCTURE; X RAY CRYSTALLOGRAPHY;

HUMAN HERPESVIRUS 4; MUS; PRIMATES;

ANIMALS; ANTIBODIES, NEUTRALIZING; CRYSTALLOGRAPHY, X-RAY; DRUG DESIGN; FEMALE; HERPESVIRUS 4, HUMAN; HERPESVIRUS VACCINES; MACACA FASCICULARIS; MICE; MICE, INBRED BALB C; NANOPARTICLES; RECEPTORS, COMPLEMENT 3D; RECOMBINANT PROTEINS;

EID: 84940461031     PISSN: 00928674     EISSN: 10974172     Source Type: Journal    
DOI: 10.1016/j.cell.2015.07.043     Document Type: Article

References (58)

1. M.F. Bachmann, and R.M. Zinkernagel Neutralizing antiviral B cell responses Annu. Rev. Immunol. 15 1997 235 270
2. M.F. Bachmann, U. Kalinke, A. Althage, G. Freer, C. Burkhart, H. Roost, M. Aguet, H. Hengartner, and R.M. Zinkernagel The role of antibody concentration and avidity in antiviral protection Science 276 1997 2024 2027
3. M.L. Baker, J. Zhang, S.J. Ludtke, and W. Chiu Cryo-EM of macromolecular assemblies at near-atomic resolution Nat. Protoc. 5 2010 1697 1708
4. R. Blasco, and B. Moss Selection of recombinant vaccinia viruses on the basis of plaque formation Gene 158 1995 157 162
5. Z. Chen, P. Earl, J. Americo, I. Damon, S.K. Smith, F. Yu, A. Sebrell, S. Emerson, G. Cohen, R.J. Eisenberg, and et al. Characterization of chimpanzee/human monoclonal antibodies to vaccinia virus A33 glycoprotein and its variola virus homolog in vitro and in a vaccinia virus mouse protection model J. Virol. 81 2007 8989 8995
6. Z. Chen, K. Chumakov, E. Dragunsky, D. Kouiavskaia, M. Makiya, A. Neverov, G. Rezapkin, A. Sebrell, and R. Purcell Chimpanzee-human monoclonal antibodies for treatment of chronic poliovirus excretors and emergency postexposure prophylaxis J. Virol. 85 2011 4354 4362
7. Z. Chen, E.R. Fischer, D. Kouiavskaia, B.T. Hansen, S.J. Ludtke, B. Bidzhieva, M. Makiya, L. Agulto, R.H. Purcell, and K. Chumakov Cross-neutralizing human anti-poliovirus antibodies bind the recognition site for cellular receptor Proc. Natl. Acad. Sci USA 110 2013 20242 20247
8. K.J. Cho, H.J. Shin, J.H. Lee, K.J. Kim, S.S. Park, Y. Lee, C. Lee, S.S. Park, and K.H. Kim The crystal structure of ferritin from Helicobacter pylori reveals unusual conformational changes for iron uptake J. Mol. Biol. 390 2009 83 98
9. J.I. Cohen, A.S. Fauci, H. Varmus, and G.J. Nabel Epstein-Barr virus: an important vaccine target for cancer prevention Sci. Transl. Med. 3 2011 107fs7
10. S.A. Connolly, J.O. Jackson, T.S. Jardetzky, and R. Longnecker Fusing structure and function: a structural view of the herpesvirus entry machinery Nat. Rev. Microbiol. 9 2011 369 381
11. D.C. Ekiert, A.K. Kashyap, J. Steel, A. Rubrum, G. Bhabha, R. Khayat, J.H. Lee, M.A. Dillon, R.E. O'Neil, A.M. Faynboym, and et al. Cross-neutralization of influenza A viruses mediated by a single antibody loop Nature 489 2012 526 532
12. S.L. Elliott, A. Suhrbier, J.J. Miles, G. Lawrence, S.J. Pye, T.T. Le, A. Rosenstengel, T. Nguyen, A. Allworth, S.R. Burrows, and et al. Phase I trial of a CD8+ T-cell peptide epitope-based vaccine for infectious mononucleosis J. Virol. 82 2008 1448 1457
13. M.A. Epstein, B.G. Achong, and Y.M. Barr Virus Particles in Cultured Lymphoblasts from Burkitt's Lymphoma Lancet 1 1964 702 703
14. M.A. Epstein, A.J. Morgan, S. Finerty, B.J. Randle, and J.K. Kirkwood Protection of cottontop tamarins against Epstein-Barr virus-induced malignant lymphoma by a prototype subunit vaccine Nature 318 1985 287 289
15. J.D. Fingeroth, J.J. Weis, T.F. Tedder, J.L. Strominger, P.A. Biro, and D.T. Fearon Epstein-Barr virus receptor of human B lymphocytes is the C3d receptor CR2 Proc. Natl. Acad. Sci. USA 81 1984 4510 4514
16. I.S. Georgiev, M. Gordon Joyce, T. Zhou, and P.D. Kwong Elicitation of HIV-1-neutralizing antibodies against the CD4-binding site Curr. Opin. HIV AIDS 8 2013 382 392
17. S.Y. Gu, T.M. Huang, L. Ruan, Y.H. Miao, H. Lu, C.M. Chu, M. Motz, and H. Wolf First EBV vaccine trial in humans using recombinant vaccinia virus expressing the major membrane antigen Dev. Biol. Stand. 84 1995 171 177
18. G.J. Hoffman, S.G. Lazarowitz, and S.D. Hayward Monoclonal antibody against a 250,000-dalton glycoprotein of Epstein-Barr virus identifies a membrane antigen and a neutralizing antigen Proc. Natl. Acad. Sci. USA 77 1980 2979 2983
19. D.J. Huard, K.M. Kane, and F.A. Tezcan Re-engineering protein interfaces yields copper-inducible ferritin cage assembly Nat. Chem. Biol. 9 2013 169 176
20. L.M. Hutt-Fletcher Epstein-Barr virus entry J. Virol. 81 2007 7825 7832
21. D.J. Irvine, M.A. Swartz, and G.L. Szeto Engineering synthetic vaccines using cues from natural immunity Nat. Mater. 12 2013 978 990
22. A. Jääskeläinen, R.R. Harinen, U. Lamminmäki, T. Korpimäki, L.J. Pelliniemi, T. Soukka, and M. Virta Production of apoferritin-based bioinorganic hybrid nanoparticles by bacterial fermentation followed by self-assembly Small 3 2007 1362 1367
23. J. Jardine, J.P. Julien, S. Menis, T. Ota, O. Kalyuzhniy, A. McGuire, D. Sok, P.S. Huang, S. MacPherson, M. Jones, and et al. Rational HIV immunogen design to target specific germline B cell receptors Science 340 2013 711 716
24. M.G. Joyce, M. Kanekiyo, L. Xu, C. Biertümpfel, J.C. Boyington, S. Moquin, W. Shi, X. Wu, Y. Yang, Z.Y. Yang, and et al. Outer domain of HIV-1 gp120: antigenic optimization, structural malleability, and crystal structure with antibody VRC-PG04 J. Virol. 87 2013 2294 2306
25. J.P. Julien, P.S. Lee, and I.A. Wilson Structural insights into key sites of vulnerability on HIV-1 Env and influenza HA Immunol. Rev. 250 2012 180 198
26. M. Kanekiyo, C.J. Wei, H.M. Yassine, P.M. McTamney, J.C. Boyington, J.R. Whittle, S.S. Rao, W.P. Kong, L. Wang, and G.J. Nabel Self-assembling influenza nanoparticle vaccines elicit broadly neutralizing H1N1 antibodies Nature 499 2013 102 106
27. S. Khurana, N. Verma, J.W. Yewdell, A.K. Hilbert, F. Castellino, M. Lattanzi, G. Del Giudice, R. Rappuoli, and H. Golding MF59 adjuvant enhances diversity and affinity of antibody-mediated immune response to pandemic influenza vaccines Sci. Transl. Med. 3 2011 85ra48
28. T. Krey, A. Meola, Z.Y. Keck, L. Damier-Piolle, S.K. Foung, and F.A. Rey Structural basis of HCV neutralization by human monoclonal antibodies resistant to viral neutralization escape PLoS Pathog. 9 2013 e1003364
29. P.S. Lee, R. Yoshida, D.C. Ekiert, N. Sakai, Y. Suzuki, A. Takada, and I.A. Wilson Heterosubtypic antibody recognition of the influenza virus hemagglutinin receptor binding site enhanced by avidity Proc. Natl. Acad. Sci. USA 109 2012 17040 17045
30. C.C. Lee, L.L. Lin, W.E. Chan, T.P. Ko, J.S. Lai, and A.H. Wang Structural basis for the antibody neutralization of herpes simplex virus Acta Crystallogr. D Biol. Crystallogr. 69 2013 1935 1945
31. C.Q. Li, E. Soistman, and D.C. Carter Ferritin nanoparticle technology. A new platform for antigen presentation and vaccine development Ind. Biotechnol. 2 2006 143 147
32. D. Lingwood, P.M. McTamney, H.M. Yassine, J.R. Whittle, X. Guo, J.C. Boyington, C.J. Wei, and G.J. Nabel Structural and genetic basis for development of broadly neutralizing influenza antibodies Nature 489 2012 566 570
33. J. Luka, R.C. Chase, and G.R. Pearson A sensitive enzyme-linked immunosorbent assay (ELISA) against the major EBV-associated antigens. I. Correlation between ELISA and immunofluorescence titers using purified antigens J. Immunol. Methods 67 1984 145 156
34. B. Machiels, C. Lété, A. Guillaume, J. Mast, P.G. Stevenson, A. Vanderplasschen, and L. Gillet Antibody evasion by a gammaherpesvirus O-glycan shield PLoS Pathog. 7 2011 e1002387
35. A. McLellan Mid Staffordshire inquiry. Too long, too late but Francis can still help make the NHS better Health Serv. J. 123 2013 3
36. F.C. Meldrum, B.R. Heywood, and S. Mann Magnetoferritin: in vitro synthesis of a novel magnetic protein Science 257 1992 522 523
37. G. Meng, X. Zhang, P. Plevka, Q. Yu, P. Tijssen, and M.G. Rossmann The structure and host entry of an invertebrate parvovirus J. Virol. 87 2013 12523 12530
38. M. Moutschen, P. Léonard, E.M. Sokal, F. Smets, M. Haumont, P. Mazzu, A. Bollen, F. Denamur, P. Peeters, G. Dubin, and M. Denis Phase I/II studies to evaluate safety and immunogenicity of a recombinant gp350 Epstein-Barr virus vaccine in healthy adults Vaccine 25 2007 4697 4705
39. J.G. Ogembo, L. Kannan, I. Ghiran, A. Nicholson-Weller, R.W. Finberg, G.C. Tsokos, and J.D. Fingeroth Human complement receptor type 1/CD35 is an Epstein-Barr Virus receptor Cell Rep. 3 2013 371 385
40. Y. Okuno, Y. Isegawa, F. Sasao, and S. Ueda A common neutralizing epitope conserved between the hemagglutinins of influenza A virus H1 and H2 strains J. Virol. 67 1993 2552 2558
41. M.G. Rossmann, R. Bernal, and S.V. Pletnev Combining electron microscopic with x-ray crystallographic structures J. Struct. Biol. 136 2001 190 200
42. J. Sashihara, P.D. Burbelo, B. Savoldo, T.C. Pierson, and J.I. Cohen Human antibody titers to Epstein-Barr Virus (EBV) gp350 correlate with neutralization of infectivity better than antibody titers to EBV gp42 using a rapid flow cytometry-based EBV neutralization assay Virology 391 2009 249 256
43. J. Sashihara, Y. Hoshino, J.J. Bowman, T. Krogmann, P.D. Burbelo, V.M. Coffield, K. Kamrud, and J.I. Cohen Soluble rhesus lymphocryptovirus gp350 protects against infection and reduces viral loads in animals that become infected with virus after challenge PLoS Pathog. 7 2011 e1002308
44. F. Serafini-Cessi, N. Malagolini, M. Nanni, F. Dall'Olio, G. Campadelli-Fiume, J. Tanner, and E. Kieff Characterization of N- and O-linked oligosaccharides of glycoprotein 350 from Epstein-Barr virus Virology 170 1989 1 10
45. E.M. Sokal, K. Hoppenbrouwers, C. Vandermeulen, M. Moutschen, P. Léonard, A. Moreels, M. Haumont, A. Bollen, F. Smets, and M. Denis Recombinant gp350 vaccine for infectious mononucleosis: a phase 2, randomized, double-blind, placebo-controlled trial to evaluate the safety, immunogenicity, and efficacy of an Epstein-Barr virus vaccine in healthy young adults J. Infect. Dis. 196 2007 1749 1753
46. M. Sutter, D. Boehringer, S. Gutmann, S. Günther, D. Prangishvili, M.J. Loessner, K.O. Stetter, E. Weber-Ban, and N. Ban Structural basis of enzyme encapsulation into a bacterial nanocompartment Nat. Struct. Mol. Biol. 15 2008 939 947
47. G. Szakonyi, M.G. Klein, J.P. Hannan, K.A. Young, R.Z. Ma, R. Asokan, V.M. Holers, and X.S. Chen Structure of the Epstein-Barr virus major envelope glycoprotein Nat. Struct. Mol. Biol. 13 2006 996 1001
48. J. Tanner, Y. Whang, J. Sample, A. Sears, and E. Kieff Soluble gp350/220 and deletion mutant glycoproteins block Epstein-Barr virus adsorption to lymphocytes J. Virol. 62 1988 4452 4464
49. D.A. Thorley-Lawson, and K. Geilinger Monoclonal antibodies against the major glycoprotein (gp350/220) of Epstein-Barr virus neutralize infectivity Proc. Natl. Acad. Sci. USA 77 1980 5307 5311
50. D.A. Thorley-Lawson, and C.A. Poodry Identification and isolation of the main component (gp350-gp220) of Epstein-Barr virus responsible for generating neutralizing antibodies in vivo J. Virol. 43 1982 730 736
51. J. Trikha, E.C. Theil, and N.M. Allewell High resolution crystal structures of amphibian red-cell L ferritin: potential roles for structural plasticity and solvation in function J. Mol. Biol. 248 1995 949 967
52. S.M. Tugizov, J.W. Berline, and J.M. Palefsky Epstein-Barr virus infection of polarized tongue and nasopharyngeal epithelial cells Nat. Med. 9 2003 307 314
53. E.N. van den Brink, J. Ter Meulen, F. Cox, M.A. Jongeneelen, A. Thijsse, M. Throsby, W.E. Marissen, P.M. Rood, A.B. Bakker, H.R. Gelderblom, and et al. Molecular and biological characterization of human monoclonal antibodies binding to the spike and nucleocapsid proteins of severe acute respiratory syndrome coronavirus J. Virol. 79 2005 1635 1644
54. Z. Wang, C. Li, M. Ellenburg, E. Soistman, J. Ruble, B. Wright, J.X. Ho, and D.C. Carter Structure of human ferritin L chain Acta Crystallogr. D Biol. Crystallogr. 62 2006 800 806
55. J.R. Whittle, R. Zhang, S. Khurana, L.R. King, J. Manischewitz, H. Golding, P.R. Dormitzer, B.F. Haynes, E.B. Walter, M.A. Moody, and et al. Broadly neutralizing human antibody that recognizes the receptor-binding pocket of influenza virus hemagglutinin Proc. Natl. Acad. Sci. USA 108 2011 14216 14221
56. X. Wu, Z.Y. Yang, Y. Li, C.M. Hogerkorp, W.R. Schief, M.S. Seaman, T. Zhou, S.D. Schmidt, L. Wu, L. Xu, and et al. Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1 Science 329 2010 856 861
57. K.A. Young, A.P. Herbert, P.N. Barlow, V.M. Holers, and J.P. Hannan Molecular basis of the interaction between complement receptor type 2 (CR2/CD21) and Epstein-Barr virus glycoprotein gp350 J. Virol. 82 2008 11217 11227
58. T. Zhou, I. Georgiev, X. Wu, Z.Y. Yang, K. Dai, A. Finzi, Y.D. Kwon, J.F. Scheid, W. Shi, L. Xu, and et al. Structural basis for broad and potent neutralization of HIV-1 by antibody VRC01 Science 329 2010 811 817